Screener
Bristol-Myers Squibb BMY Revlimid — Total Revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
| Dollars in millions | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total Growth Portfolio | 7,560 | 6,596 | 13,787 | 12,159 |
| Legacy Portfolio | ||||
| Eliquis | 4,481 | 3,680 | 8,617 | 7,245 |
| Revlimid | 425 | 838 | 773 | 1,774 |
| Pomalyst/Imnovid | 204 | 708 | 717 | 1,366 |
| Sprycel | 88 | 120 | 160 | 295 |
| Abraxane | 55 | 105 | 105 | 210 |
| Other Legacy products(b) | 170 | 223 | 326 | 421 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Bristol-Myers Squibb's revlimid — total revenues?
- Bristol-Myers Squibb (BMY) reported revlimid — total revenues of $425M in Q2 2026.
- How has Bristol-Myers Squibb's revlimid — total revenues changed year-over-year?
- Bristol-Myers Squibb's revlimid — total revenues decreased by 49.3% year-over-year, from $838M to $425M.
- What is the long-term trend for Bristol-Myers Squibb's revlimid — total revenues?
- Over 4 years (2021 to 2025), Bristol-Myers Squibb's revlimid — total revenues has grown at a -30.7% compound annual growth rate (CAGR), from $12.82B to $2.95B.
- What does revlimid — total revenues mean?
- This metric represents the total global net sales generated by the pharmaceutical product Revlimid. As a key oncology asset, it reflects the company's market position in treating hematologic malignancies and serves as a critical component of the firm's overall revenue stream. Monitoring this figure is essential for assessing the impact of patent expirations and the introduction of generic competition on the company's top-line performance.
Ask your AI about Bristol-Myers Squibb's revlimid — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude